Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

Informazioni relative al progetto

HEcoPerMed

ID dell’accordo di sovvenzione: 824997

DOI

10.3030/824997

Progetto chiuso

Data della firma CE 7 Novembre 2018

Data di avvio 1 Gennaio 2019

Data di completamento 30 Giugno 2022

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 1 998 437,50

Contributo UE

€ 1 998 437,50

Coordinato da

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH
Austria

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Other (3)

Budget impact models

Budget impact models developed for the 3 case studies

Cost-effectiveness models

Costeffectiveness models developed for the 3 case studies

Recommendation on the refinement of the guidance developed in WP1

Documents, reports (11)

All models populated with input data from 3 EU Member States
Report of the Stakeholder Conference
Guidance paper on health economic modelling of per-sonalised medicine
Checklist methodological quality

Checklist to assess the methodological quality of model-based economic evaluations of personalised medicine

financing and payment models

A set of appropriate financing and payment models for personalised medicine for different types of health care systems in EU

action plan

An action plan to adopt appropriate financing and payment models for personalised medicine across EU

Synthesis Report of virtual WS1 and 2
Overview of major findings from interviews
Report of the WS2
"Report on ""The Benefits & Challenges"""

Report on The Benefits Challenges of Personalised Medicine for the European Social Models of Health Care

Workshop 1 report

Open Research Data Pilot (1)

Data Management Plan

Pubblicazioni

Peer reviewed articles (3)

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Autori: Apostolos Tsiachristas, Grant Vallance, Rositsa Koleva-Kolarova, Harriet Taylor, Luke Solomons, Giovanni Rizzo, Catherine Chaytor, Junel Miah, Sarah Wordsworth & A. Bassim Hassan
Pubblicato in: BMC cancer, 2022, ISSN 1471-2407
Editore: BioMed Central
DOI: 10.1186/s12885-022-09576-3

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Autori: Rositsa Koleva-Kolarova; James Buchanan
Pubblicato in: Applied Health Economics and Health Policy, Numero 5, 2022, ISSN 1179-1896
Editore: Springer
DOI: 10.1007/s40258-021-00714-9

The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis

Autori: Heleen Vellekoop, Matthijs Versteegh, Simone Huygens, Isaac Corro-Ramos, László Szilberhorn, Tamás Zelei, Balázs Nagy, Apostolos Tsiachristas, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken
Pubblicato in: Value in Health, 2022, ISSN 1098-3015
Editore: Blackwell Publishing Inc.
DOI: 10.1016/j.jval.2022.01.006